AMAvril Metcalfe-Roach

Avril Metcalfe-Roach

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Avril Metcalfe-Roach has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The role of the gut microbiome in Parkinson’s disease

    by Avril Metcalfe-Roach, B. Brett Finlay


  • Open Access

    A Randomized Safety and Feasibility Crossover Trial of two Mediterranean-Ketogenic Interventions in Individuals with Parkinson’s Disease

    by Kira N Tosefsky, Joyce S. T. Lam, Yolanda N. Wang, Shayan Keymanesh, Annie J. Kuan, Avril Metcalfe-Roach, Mihai S. Cirstea, Matthew A. Sacheli, B. Brett Finlay, Tamara R. Cohen, et al.

    BACKGROUND: Both Mediterranean and ketogenic diets have been proposed as nutritional interventions in Parkinson’s disease (PD). Combined approaches may offer maximal benefits. OBJECTIVE: Assess the feasibility, safety and exploratory efficacy of two Mediterranean-ketogenic dietary interventions in individuals with PD (PwP). METHODS: In this Phase II, random-order crossover study, PwP followed two 8-week dietary interventions, separated by an 8-week washout: 1) a high-fat, low-carbohydrate Mediterranean diet (MeDi-KD) and 2) a standard Mediterranean diet supplemented with medium chain triglycerides (MeDi-MCT). RESULTS: Of 52 participants randomized, 48 started the trial. Forty-one (79%) participants completed at least one and 33 (63%) completed both intervention phases. There were no intervention-related serious adverse events, nor any significant changes in plasma lipid profiles. Seventy-three percent and 92% of participants reported deviating from the MeDi-KD and MeDi-MCT no more than a few times per month, respectively. Moderate Mediterranean Diet Adherence Scores of 6.7 (SD: 1.6) and 7.2 (SD: 2.3) were achieved during the MeDi-KD and MeDi-MCT, respectively, out of a maximum of 14. Fifty percent of participants were in nutritional ketosis (BHB >0.5 mM) at follow-up for the MeDi-KD, as compared with only 1 (3%) participant following the MeDi-MCT. MDS-UPDRS Part II and IV scores decreased by a mean of -1.4 (SD: 4.2; p=0.039) and -1.0 (SD: 3.0; p=0.044) points, respectively, following the MeDi-MCT. CONCLUSIONS: Mediterranean-ketogenic interventions appear safe and potentially beneficial in PwP. Behavioral strategies to optimize adherence should be employed in future phase III trials. TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov: NCT05469997 . PLAIN LANGUAGE SUMMARY: Many patients want to know what the best diet is to follow for their Parkinson’s disease. Previous studies have suggested benefits of both ketogenic diets, which are high in fats and low in carbohydrates, and Mediterranean-style diets. Combining these two approaches could offer maximal advantages, while reducing the challenges of following a strict ketogenic diet. The aim of this study was to test whether so-called “Mediterranean-ketogenic” diets would be safe and practical for patients with Parkinson’s disease to follow. Early indicators of potential clinical benefit were also assessed. Fifty-two participants were randomly assigned to follow two types of Mediterranean-ketogenic diets for eight weeks each, with an eight-week break in between. The two interventions were: 1) A high-fat, low carbohydrate version of a Mediterranean diet (MeDi-KD) and 2) A Mediterranean diet administered with a ketogenic supplement, medium-chain triglyceride oil (MeDi-MCT). Forty-eight people started the study, 41 completed at least one diet intervention phase and 33 completed both intervention phases. No serious side effects were reported. Although most participants felt they followed the diets closely, objective measures of adherence suggested room for improvement. The MeDi-MCT diet led to small but significant improvements in patient-reported motor activities of daily living and motor complications. Longer-term studies are needed to validate these findings. Future trials should incorporate behavioral coaching techniques to better help participants follow the diets.


  • Open Access

    Metagenomic Analysis Reveals Large‐Scale Disruptions of the Gut Microbiome in Parkinson's Disease

    by Avril Metcalfe‐Roach, Mihai S. Cirstea, Adam C. Yu, Hena R. Ramay, Olabisi Coker, Seti Boroomand, Faezeh Kharazyan, Davide Martino, Laura K. Sycuro, Silke Appel‐Cresswell, et al.

    Background: Parkinson's disease (PD) has been consistently linked to alterations within the gut microbiome. Objective: Our goal was to identify microbial features associated with PD incidence and progression. Methods: Metagenomic sequencing was used to characterize taxonomic and functional changes to the PD microbiome and to explore their relation to bacterial metabolites and disease progression. Motor and non‐motor symptoms were tracked using Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS‐UPDRS) and levodopa equivalent dose across ≤5 yearly study visits. Stool samples were collected at baseline for metagenomic sequencing (176 PD, 100 controls). Results: PD‐derived stool samples had reduced intermicrobial connectivity and seven differentially abundant species compared to controls. A suite of bacterial functions differed between PD and controls, including depletion of carbohydrate degradation pathways and enrichment of ribosomal genes. Faecalibacterium prausnitzii ‐specific reads contributed significantly to more than half of all differentially abundant functional terms. A subset of disease‐associated functional terms correlated with faster progression of MDS‐UPDRS part IV and separated those with slow and fast progression with moderate accuracy within a random forest model (area under curve = 0.70). Most PD‐associated microbial trends were stronger in those with symmetric motor symptoms. Conclusion: We provide further evidence that the PD microbiome is characterized by reduced intermicrobial communication and a shift to proteolytic metabolism in lieu of short‐chain fatty acid production, and suggest that these microbial alterations may be relevant to disease progression. We also describe how our results support the existence of gut‐first versus brain‐first PD subtypes. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Microbiome changes under enteral deprivation are dynamic and dependent on intestinal location

    by Haggai Bar‐Yoseph, Avril Metcalfe‐Roach, Mihai Cirstea, B. Brett Finlay

    Background: The microbiome has a pivotal role in intestinal health, and nutrition has a major role shaping its structure. Enteral deprivation, in which no oral/enteral nutrition is administered, is common in hospitalized/gastrointestinal patients. The dynamics that enteral deprivation exerts on the microbial community, specifically in the small intestine, are not well understood.Methods: Enteral deprivation was modeled with exclusive parenteral nutrition (EPN) mice. Mice were allocated to receive either EPN or saline and chow (control) and euthanized after 0, 2, 4, or 6 days. DNA was extracted from jejunum, ileum, and colon content. 16S sequencing was used to compare changes in microbial communities between groups. Functional pathways were predicted using Phylogenetic Investigation of Communities by Reconstruction of Unobserved States.Results: EPN‐treated mice showed community changes throughout the intestine. Beta diversity in colon showed clear separation between the groups (Bray‐Curtis, P < 0.001). Time‐dependent dynamics were seen in ileal but not jejunal samples. Alpha diversity was lower in the colon of EPN mice compared with control/baseline mice (Chao1, P < 0.01) but not in ileum/jejunum. Progressive loss of single‐taxon domination was seen, most notably in the small intestine. This was accompanied by increases/decreases in specific taxa. A clear separation was seen in the functional capacity of the community between fed and enterally deprived mice at the ileum and colon, which was observed early on.Conclusions: Enteral deprivation disturbs the microbial community in a spatial and dynamic manner. There should be further focus on studying the effect of these changes on the host.


  • Multiple micronutrient deficiencies in early life cause multi-kingdom alterations in the gut microbiome and intrinsic antibiotic resistance genes in mice

    by Paula T. Littlejohn, Avril Metcalfe-Roach, Erick Cardenas Poire, Ravi Holani, Haggai Bar-Yoseph, Yiyun M. Fan, Sarah E. Woodward, B. Brett Finlay

    Globally, ~340 million children suffer from multiple micronutrient deficiencies, accompanied by high pathogenic burden and death due to multidrug-resistant bacteria. The microbiome is a reservoir of antimicrobial resistance (AMR), but the implications of undernutrition on the resistome is unclear. Here we used a postnatal mouse model that is deficient in multiple micronutrients (that is, zinc, folate, iron, vitamin A and vitamin B12 deficient) and shotgun metagenomic sequencing of faecal samples to characterize gut microbiome structure and functional potential, and the resistome. Enterobacteriaceae were enriched in micronutrient-deficient mice compared with mice fed an isocaloric experimental control diet. The mycobiome and virome were also altered with multiple micronutrient deficiencies including increased fungal pathogens such as Candida dubliniensis and bacteriophages. Despite being antibiotic naïve, micronutrient deficiency was associated with increased enrichment of genes and gene networks encoded by pathogenic bacteria that are directly or indirectly associated with intrinsic antibiotic resistance. Bacterial oxidative stress was associated with intrinsic antibiotic resistance in these mice. This analysis reveals multi-kingdom alterations in the gut microbiome as a result of co-occurring multiple micronutrient deficiencies and the implications for antibiotic resistance.


  • Open Access

    Early-life exposure to multiple micronutrient deficiencies induces clinically-relevant antibiotic resistance in a pre-clinical murine model

    by Paula Littlejohn, Avril Metcalfe-Roach, Ravi Holani, Haggai Bar-Yoseph, Yiyun Fan, B Finlay

    Globally, ~340 million children (<5 years) suffer from multiple micronutrient deficiencies, accompanied by high pathogenic burden and death due to multi-drug resistant bacteria. The role of early-life micronutrient deficiencies in mitigating antibiotic resistance within the host microbiota remains unexplored. We developed a postnatal preclinical murine model deficient in multiple micronutrients: zinc, folate, iron, vitamin A, and vitamin B12. Fecal metagenomic sequencing after dietary exposure revealed enrichment in the relative abundance of pathobionts and antibiotic resistance mechanisms including efflux pumps, target drug site alteration, antibiotic degrading enzymes, permeability, and acquisition of antibiotic resistance genes (ARGs). Despite being antibiotic naïve, we observed increased abundance of genes encoding resistance to several antibiotic classes: tetracycline, vancomycin, methicillin, fosfomycin, aminoglycosides and glycopeptides. Moreover, in vitro antibiotic susceptibility testing revealed clinically-relevant resistance to multiple antibiotic classes, namely vancomycin, methicillin, amoxicillin and erythromycin in mice fed the low-micronutrient diet. These novel findings present an unappreciated and profound role of cooccurring multiple micronutrient deficiencies in contributing to the global burden of antibiotic resistance, with significant clinical implications for undernourished children living in low-to-mid income countries.

  • Open Access

    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease

    by Avril Metcalfe‐Roach, Adam C. Yu, Ella Golz, Mihai Cirstea, Kristen Sundvick, Daniel Kliger, Liam H. Foulger, Melissa Mackenzie, B. Brett Finlay, Silke Appel‐Cresswell

    Background: The MIND diet has been linked with prevention of Alzheimer's disease and cognitive decline but has not been fully assessed in the context of Parkinson's disease (PD). The objective of the present study was to determine whether MIND diet adherence is associated with the age of Parkinson's disease onset in a manner superior to that of the Mediterranean diet.Methods: Food Frequency Questionnaires from 167 participants with PD and 119 controls were scored for MIND and 2 versions of Mediterranean diet adherence. Scores were compared between sex and disease subgroups, and PD diet adherence was correlated with age at onset using univariate and multivariate linear models.Results: The female subgroup adhered more closely to the MIND diet than the male subgroup, and diet scores were not modified by disease status. Later age of onset correlated most strongly with MIND diet adherence in the female subgroup, corresponding to differences of up to 17.4 years (P < 0.001) between low and high dietary tertiles. Greek Mediterranean adherence was also significantly associated with later PD onset across all models (P = 0.05–0.03). Conversely, only Greek Mediterranean diet adherence remained correlated with later onset across all models in men, with differences of up to 8.4 years (P = 0.002).Conclusions: This cross‐sectional study found a strong correlation between age of onset of PD and dietary habits, suggesting that nutritional strategies may be an effective tool to delay PD onset. Further studies may help to elucidate potential nutrition‐related sex‐specific pathophysiological mechanisms and differential prevalence rates in PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    MIND diet associated with later onset of Parkinson’s disease

    by A Metcalfe-Roach, Ac Yu, E Golz, K Sundvick, Cirstea, D Kliger, Lh Foulger, M Mackenzie, Bb Finlay, S Appel-Cresswell

    Background The MIND diet has been linked with prevention of Alzheimer’s disease and cognitive decline but has not been fully assessed in the context of Parkinson’s disease (PD). Objective To determine whether MIND diet adherence is associated with the age of Parkinson’s disease onset in a manner superior to that of the Mediterranean diet. Methods Food Frequency Questionnaires from 167 participants with PD and 119 controls were scored for MIND and two versions of Mediterranean diet adherence. Scores were compared between sex and disease subgroups, and PD diet adherence was correlated with age of onset using univariate and multivariate linear models. Results The female subgroup adhered more closely to the MIND diet than the males, and diet scores were not modified by disease status. Later age of onset correlated most strongly with MIND diet adherence in the female subgroup, corresponding to differences of up to 17.4 years (pConclusions This cross-sectional study finds a strong correlation of age of onset of PD with dietary habits, suggesting that nutritional strategies may be an effective tool to delay PD onset. Further studies may help to elucidate potential nutrition-related sex-specific pathophysiological mechanisms and differential prevalence rates in PD.


  • LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis

    by M. C. Poffenberger, A. Metcalfe-Roach, E. Aguilar, J. Chen, B. E. Hsu, A. H. Wong, R. M. Johnson, B. Flynn, B. Samborska, E. H. Ma, et al.

    Inflammation promotes gut polyposis: Peutz–Jeghers Syndrome (PJS) causes benign polyps in the gut and a higher risk of several cancers caused by mutations in the tumor suppressor gene STK11 , which encodes liver kinase B1 (LKB1). LKB1's role in this disease is thought to be related to its tumor suppressor function. Now, Poffenberger et al. show that the T cell–specific heterozygous deletion of Stk11 is sufficient to reproduce PJS symptoms in mice (see the Perspective by Hollstein and Shaw). Polyps in mice and humans are characterized by immune cell infiltration, enhanced STAT3 signaling, and increased levels of inflammatory cytokines such as interleukin-6 (IL-6). Targeting STAT3 signaling, IL-6, or T cells ameliorated the polyps, suggesting potential therapies for this disease. Science , this issue p. 406 ; see also p. 332